Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$149.52+3.19 (+2.18%)
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Interest Income: $35M in Q2 2026, down 49.3% from a year earlier.
Latest, Q2 2026
35
Period ended Jun 30, 2026
Change on a year earlier
-49.3%
69 in Q2 2025
History
65 quarters
Since Q2 2009
Sources
61
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-07) ↗
Reported in Postgres DB financial_values.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Merck Interest Income ($M), quarterly Q2 2009–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/db-inc-int-inc
See every metric in the Merck KPI table. Data updated Oct 26, 2026.